Question explored with the scientific record
Are there any links between hep b, MMR and onset of tics in adults?
The short version: there is no direct evidence that hepatitis B or MMR vaccination triggers tics in adults, but the question has never been properly studied in the specific population.
A 2024 VAERS analysis found that in infants up to 3 years, speech disorders and autism spectrum reports were "highly associated" with both MMR and hepatitis B vaccines [3]. That is a very different population than adults with tics, and VAERS is a passive reporting system where mere association does not prove causation. The same study noted the associations could reflect reporting bias rather than true effects [3]. A separate 2025 VAERS analysis of hepatitis B vaccine reports found disproportionate signals for tendon fibrosis (reporting odds ratio 252), myofascitis, and fasciitis but did not examine tic disorders at all [2].
The broader neurological evidence for MMR in adults is limited to rare case reports: a 30-year-old woman who developed optic neuritis 5 days after MMR [4], and an 11-year-old girl with transverse myelitis 21 days after hepatitis B vaccine [1]. Neither is about tics. The mechanistic question is plausible — molecular mimicry and immune activation can disturb basal ganglia circuits, and the link between streptococcal infection and tic exacerbation (PANDAS) is well-documented outside this retrieval, with a meta-analysis showing elevated anti-streptolysin O titers in tic disorder patients [5]. But a plausible mechanism is not proof that these vaccines cause adult-onset tics.
The evidence that exists was not designed to answer this question. No study in this retrieval compared tic rates in vaccinated versus unvaccinated adults. No long-term safety trial of hepatitis B or MMR vaccine in adults tracked tic disorders as an endpoint. The question sits in a blind spot the system does not look at.
My call: the literature provides no direct evidence linking hepatitis B or MMR vaccination to adult-onset tics, but the question has never been studied with the right design — a comparison of tic rates between vaccinated and unvaccinated adults followed over time. Confidence: not clear because the relevant study does not exist and absent evidence is not evidence of safety.
Sources used 5
-
Transverse myelitis following hepatitis B vaccination
A single-patient case report describing transverse myelitis occurring 21 days after hepatitis B vaccination in an 11-year-old girl, with discussion of potential immune-mediated mechanisms and the uncertainty of a causal link.
DOI: 10.1016/S0168-8278(05)80589-6 -
Musculoskeletal adverse events reported post-hepatitis B vaccination in the vaccine adverse event reporting system
In 76,887 VAERS reports, hepatitis B vaccine musculoskeletal signals appeared (strongest tendon fibrosis, myofascitis, fasciitis), though SOC overall was not disproportionate; most events occurred within 30 days; male sex and combination vaccination were death-associated.
DOI: 10.3389/fpubh.2025.1560973 -
Signatures of neurological adverse events after vaccination
A retrospective VAERS analysis of age-stratified neurological adverse events reported after vaccination identified high associations of aphasia, autism spectrum disorder, and speech disorder with MMR and hepatitis B vaccines in infants up to 3 years, febrile convulsion and synco…
DOI: 10.36922/an.2258 -
Unilateral Optic Neuritis: A Rare Complication after Measles-Mumps-Rubella Vaccination in a 30-Year-Old Woman
Unilateral optic neuritis occurred in a healthy 30-year-old woman five days after Measles-Mumps-Rubella vaccination and resolved with high-dose corticosteroid therapy, illustrating a rare adult post-vaccination optic neuropathy.
DOI: 10.1155/2016/8740264 -
On the Connection Between Autoimmunity, tic Disorders and Obsessive-Compulsive Disorders: A Meta-Analysis on Anti-Streptolysin O Titres
This meta-analysis investigates the association between anti-streptolysin O (ASO) titres and tic disorders, revealing a significant increase in ASO levels in patients compared to healthy controls and non-psychiatric patients.
DOI: 10.1007/s11481-014-9561-1